1. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety,depression and stress. J Dent Res 2000;79:1652-8.
2. Berne RM. Physiology. 4th ed. St Louis (M0): Mosby, 1998;619-21.
3. Carlson GW. The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am2000;80:261-73.
4. Nagler RM. Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring.Biogerontology. 2004;5:223-33.
5. Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol 2000;18:525-32.
6. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:641-9.
7. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159:1245-52.
8. Hunter KD, Wilson WS. The effects ofantidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995;40:983-9.
9. Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 1997;58:112-8.
10. Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP. Omeprazole and dry mouth. ScandJGastroenterol 1995;30:216-8.
11. Bruera E, Belzile M, Neumann CM, Ford I, Harsanyi Z, Darke A. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment ofcancer pain.A randomized controlled trial. Support Care Cancer 1999;7: 280-3.
12. Hill JL, Zacny JP. Comparing the subjective, psychomotor, and physiological effects ofintravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl) 2000; 152:31-9.
13. Chilla R, Arglebe C. Pharmacotherapy ofhypertension and its significance for the function of the salivary glands (author's translation). MMW Munch Med Wochenschr 1975;117:1425-8.
14. SchoenbergerJA, Croog SH, SudilovskyA, Levine S, Baume RM. Self-reported side effects from antihypertensive drugs. A clinical trial. Quality ofLife Research Group. Am J Hypertens 1990;3:123-32.
15. Croog SH, Elias MF, Colton T, Baume RM, Leiblum SR, Jenkins CD, et al. Effects ofantihypertensive medications on quality oflife in elderly hypertensive women. Am J Hypertens 1994;7:329-39.
16. Nederfors T. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J Suppl 1996;116:1-70.
17.
Ökte
m F, Uzel Ö, Ada M, Toprak M, Cansız H, .Gülen H, Tuksan K Nazofarinks Kanserli Hastalarda Radyoterapi Sonras>Kulak Burun Boğaz Morbiditesi. Türk Otolarengoloji Arşivi, 2001;39:121-26
18. EpsteinJB, Stevenson-Moore
P
, ScullyC. Management ofxerostomia. JCanDentAssoc 192;58:140-3.
19. Epstein JB, van der Meji EH, Lunn R, Steverson-Moore P. Effects ofcompliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:268-
75
20. Porter SR, Scully C, Hegarty AM. An update ofthe etiology and management ofxerostomia.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 J;97:28-
46.
21. Singh N, Scully C, Joyston-Bechal S. Oral complications ofcancer therapies: prevention and management. Clin Oncol (R Coll Radiol) 1996;8:15-
24.
22. Pow EH, McMillan AS, Leung WK, Wong MC, Kwong DL. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma. Clin Oral Investig 2003;7(4):230-4.
23. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage
2001;22:820-50.
24.
Yüce
l E, Delibaşı E, Pediatrik kanser hastalarında kemoterapinin neden olduğu oral komplikasyonlar (Bir vakanedeniyle) GÜ Dişhek Fak Derg 1986;3:161-8..
25. AckerstaffAH, Tan IB, Rasch CR, Balm AJ, Keus RB, Schornagel JH, et al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. Arch Otolaryngol HeadNeck Surg 2002;128:1185-90.
26. Nagler RM. Effects ofradiotherapy and chemotherapeutic cytokines on a human salivary cell line. AnticancerRes 1998;18: 309-14.
27. Nagler RM, Sherman Y, Nagler A. Histopathological study ofthe human submandibular gland in graft versus host disease. J Clin Pathol 1999;52:395-7.
28. Levy S, Nagler A, Okon S, Marmary Y. Parotid salivary
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/ 58-67
Keçeci, Ağız kuruluğu ve tedavisi
65
gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model. Bone Marrow Transplant 2000;25:1073-8.
29. Demarosi F, Bez C, Sardella A, Lodi G, Carrassi A. Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation. Arch Dermatol 2002;138: 842-3.
30. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, Flournoy N, et al. Oral manifestations ofchronic graft-vhost disease. Arch Intern Med 1984;144:1591-5.
31. Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E. The lichen planus like and sclerotic phases ofthe graft versus host disease in man: an ultrastructural study of six cases. Acta Derm Venereol 1981;61:187-93.
32. Nicolatou-Galitis O, Kitra V, Van Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D, et al. The oral manifestations ofchronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med 2001;30:148-
53.
33. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391-8.
34. Bowman SJ. Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002;116:23-
7.
35. Ohtsuka S, Yanadori A, Tabata H, Yamakage A, Yamazaki S. Sarcoidosis with giant parotomegaly. Cutis 2001;68:199-200.
36. Drosos AA, Voulgari PV, Psychos DN, Tsifetaki N, Bai M. Sicca syndrome in patients with sarcoidosis. Rheumatol Int 1999;18:177-80.
37. Mbopi-Keou FX, Belec L, Teo CG, Scully C, Porter SR. Synergism between HIV and other viruses in the mouth. Lancet Infect Dis 2002;2:416-24
38. Franco-Paredas C, Rebolledo P, Folch E, Hernandez I, del Rio C. Diagnosis ofdiffuse CD8+ lymphocytosis syndrome in HIV-infected patients. AIDS Read 2002;12:408-13
39. Pedersen AM, Nauntofte B. Primary Sjögren's syndrome: oral aspects on pathogenesis, diagnostic criteria, clinical features and approaches for therapy. Expert Opin Pharmacother 2001; 2:1415-36.
40. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch MedRes 2002;33:95- 106.
41. Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000;29:20-8.
42. Hay KD, Morton RP, Wall CR. Quality oflife and nutritional studies in Sjögren's syndrome patients with
xerostomia. N Z Dent J 2001;97:128-31.
43. Rostron J, Rogers S, Longman L, Kaney S, Field EA. Health related quality oflife in patients with primary Sjogren's syndrome and xerostomia: a comparative study. Gerodontology 2002;19:53-9.
44. Little JW, Falace DA, Miller CS, Rhodus NL. Dental manegement ofmedically compromised patient (5th Ed) StLouis, Mosby, 1997;630-31.
45. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol 2000;29:341-8.
46. al-Hashimi I, Taylor SE. A new medication for treatment ofdrymouth in Sjögren's syndrome. Tex Dent J 2001;118:262-6.
47. Meyer-Lueckel H, KielbassaAM. Use ofsaliva substitutes in patients with xerostomia. Schweiz Monatsschr Zahnmed 2002; 112:1037-58.
48. Senahayake F, Piggott K, Hamilton-Miller JM. A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin 1998;14:155-9.
49. Warde P, Kroll B, O'Sullivan B, Aslanidis J, Tew-George E, Waldron J, et al. A phase II study ofBiotene in the treatment ofpostradiation xerostomia in patients with head and neck cancer. Support Care Cancer
2000;8:203-8.
50. Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double blind crossover trial ofOral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999;35:132-7.
51. Epstein JB, Stevenson-Moore P. A clinical comparative trial of saliva substitutes and radiation-induced salivary glandhypofunction. Spec Care Dentist 1992;12:21-3.
52. Samarawickrama DY. Saliva substitutes: how effective and safe are they? Oral Dis 2002;8:177-9.
53. Hooper P, Tincello DG, Richmond DH. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. Br J Urol 1997;80:414-6.
54. Momm F, Guttenberger R. Treatment ofxerostomia following radiotherapy: does age matter? Support Care Cancer2002;10: 505-8
55. Rhodus NL, Bereuter J. Clinical evaluation ofa commercially available oral moisturizer in relieving signs and symptoms ofxerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. J Otolaryngol 2000;29:28- 34.
56. Criswell MA, Sinha CK. Hyperthermic, supersaturated humidification in the treatment ofxerostomia. Laryngoscope 2001; 111:992-6.
57. Frost PM, Shirlaw PJ, Walter JD, Challacombe SJ. Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricating methods. Br Dent J 2002;193:403-
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/ 58-67
66
Keçeci, Ağız kuruluğu ve tedavisi
8.
58. Fox RI, Michelson P. Approaches to the treatment of Sjogren's syndrome. J Rheumatol Suppl 2000;61:15-
21.
59. Vivino FB. The treatment of Sjögren's syndrome patients with pilocarpine-tablets. Scan J Rheumatol Suppl 2001;115:1-9.
60. Aromdee C, Ferguson MM, Ledger R, Wall J. A pilot study ofthe disposition ofpilocarpine in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci 1999;8:81-3.
61. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment ofdry mouth and dry eye symptoms in patients with Sjögren's syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159: 174-81.
62. Bell M, Askari A, Bookman A, Frydrych S, Lamont J, McComb J, et al. Sjögren's syndrome: a critical review ofclinical management. J Rheumatol 1999;26:2051-61.
63. Taylor SE, Miller EG. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med 1999;221:14-26.
64. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. JClinOncol 2000;18: 3339-45.
65. Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002;12:4-13.
66. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002;13:181-209.
67. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N EnglJMed 1993;329:390-5.
68. Valdez IH, WolffA, Atkinson JC, Macynski AA, Fox PC. Use ofpilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848-51.
69. Joensuu H, Bostrom P, Makkonen T. Pilocarpine and carbacholine in treatment ofradiation-induced xerostomia. RadiotherOncol 1993;26:33-7.
70. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, et al. Determination ofthe efficacy oftopical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106:972-6.
71. Jacobs CD, van der Pas M. A multicenter maintenance study oforal pilocarpine tablets for radiation-induced xerostomia. Oncology(Huntingt) 1996;10:16-20.
72. Greenspan D, Daniels TE. Effectiveness ofpilocarpine inpostradiation xerostomia. Cancer 1987;59:1123-5.
73. Fox PC, Atkinson JC, Macynski AA, WolffA, Kung DS, Valdez IH, et al. Pilocarpine treatment ofsalivary gland hypofunction and dry mouth (xerostomia). Arch InternMed 1991; 151:1149-52.
74. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment ofthe consequences ofhead and neck radiotherapy. Crit Rev Oral Biol Med 2003:14:213-25.
75. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A mulitcenter, randomized, doubleblind, placebo-controlled, dose-titration study oforal pilocarpine for treatment ofradiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31.
76. Ferguson MM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1993;75:186-91.
77. Cooper RA, Cowan RA, Owens SE, Jeans SP, Roberts JK, Hillel PG, et al. Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? Eur J Nucl Med 1999;26:220-
5.
78. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol
2000;55:233-9.
79. Niedermeier W, Matthaeus C, Meyer C, Staar S, Muller RP, Schulze HJ. Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:541-9.
80. Lajtman Z, Krajina Z, Krpan D, Vincelj J, Borcic V, Popovic- Kovacic J. Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica
2000;54:65-7.
81. Frydrych AM, Davies GR, Slack-Smith LM, Heywood J. An investigation into the use of pilocarpine as a sialogogue in patients with radiation induced xerostomia. Aust Dent J 2002; 47:249-53.
82. Anonymous. Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. Prescrire Int 2002;11:99-101.
83. Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, et al. A Phase III placebo-controlled trial oforal pilocarpine in patients undergoing radiotherapy for headand- neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
84. Itthagarun A, Wei SH. Chewing gum and saliva in oral health. J Clin Dent 1997;8:159-62.
85. Warde P, Kroll B, O'Sullivan B, Aslanidis J, Tew-George E, Waldron J, et al. A phase II study ofBiotene in the treatment ofpostradiation xerostomia in patients with head and neck cancer. Support Care Cancer
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/ 58-67
Keçeci, Ağız kuruluğu ve tedavisi
67
2000;8:203-8.
86. Davies AN. A comparison ofartificial saliva and chewing gum in the management ofxerostomia in patients with advanced cancer. Palliat Med 2000;14:197-
203.
87. Erlichman M. Patient selection criteria for electrostimulation ofsalivary production in the treatment ofxerostomia secondaryto Sjogren's syndrome. Health TechnolAssess Rep 1990;8:1-7.
88. Blom M, Dawidson I, Angmar-Mansson B. The effect of acupuncture on salivary flow rates in patients with xerostomia. Oral Surg Oral Med Oral Pathol
1992;73:293-8.
89. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Mansson B. Acupuncture treatment ofpatients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B:182- 90.
90. Blom M, Lundeberg T. Long-term follow-up ofpatients treated with acupuncture for xerostomia and the influence ofadditional treatment. Oral Dis 2000;6:15-
24.
91. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys
2001;50:353-7.
92. List T, Lundeberg T, Lundstrom I, Lindstrom F, Ravald N. The effect ofacupuncture in the treatment ofpatients with primary Sjögren's syndrome. A controlled study. ActaOdontol Scand 1998;56:95-9.
93. Rydholm M, Strang P. Acupuncture for patients in hospitalbased home care suffering from xerostomia. JPalliatCare 1999;15:20-3.
94. Johnstone PA, Niemtzow RC, Riffenburgh RH. Acupuncture for xerostomia: clinical update. Cancer
2002;94:1151-6.
95. Pedersen A, Gerner N, Palmvang I, Hoier-Madsen M. Longo- Vital in the treatment of Sjögren's syndrome. Clin Exp Rheumatol 1999;17:533-8.
96. Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol Suppl 1986;61:242-5.
97. Oxholm P, Manthorpe R, Prause JU, Horrobin D. Patients with primary Sjogren's syndrome treated for two months with evening primrose oil. Scand J Rheumatol 1986;15:103-8.
98. Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000;71:352S-6S.
99. Chodorowski Z. Cappuccino coffee treatment of xerostomia in patients taking tricyclic antidepressants: preliminary report. Przegl Lek 2002;59:392-3.
100. Johansson G, Andersson G, Edwardsson S, Bjorn AL, Manthorpe R, Attstrom R. Effects ofmouthrinses with
linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation. Gerodontology 2001;18:87-94.
Thank you for copying data from http://www.arastirmax.com
